CL2018000422A1 - Diacuerpos monovalentes biespecíficos que son capaces de unirse a b7-h3 y cd3, y usos de los mismos - Google Patents

Diacuerpos monovalentes biespecíficos que son capaces de unirse a b7-h3 y cd3, y usos de los mismos

Info

Publication number
CL2018000422A1
CL2018000422A1 CL2018000422A CL2018000422A CL2018000422A1 CL 2018000422 A1 CL2018000422 A1 CL 2018000422A1 CL 2018000422 A CL2018000422 A CL 2018000422A CL 2018000422 A CL2018000422 A CL 2018000422A CL 2018000422 A1 CL2018000422 A1 CL 2018000422A1
Authority
CL
Chile
Prior art keywords
bispecific monovalent
diabodies
binding
monovalent diabodies
directed
Prior art date
Application number
CL2018000422A
Other languages
English (en)
Spanish (es)
Inventor
Kalpana Shah
Leslie S Johnson
Paul A Moore
Ezio Bonvini
Ling Huang
Ralph Alderson
Gurunadh Reddy Chichili
Original Assignee
Macrogenics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Macrogenics Inc filed Critical Macrogenics Inc
Publication of CL2018000422A1 publication Critical patent/CL2018000422A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/626—Diabody or triabody
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CL2018000422A 2015-08-17 2018-02-15 Diacuerpos monovalentes biespecíficos que son capaces de unirse a b7-h3 y cd3, y usos de los mismos CL2018000422A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562206051P 2015-08-17 2015-08-17
US201662280318P 2016-01-19 2016-01-19

Publications (1)

Publication Number Publication Date
CL2018000422A1 true CL2018000422A1 (es) 2018-08-10

Family

ID=58051498

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2018000422A CL2018000422A1 (es) 2015-08-17 2018-02-15 Diacuerpos monovalentes biespecíficos que son capaces de unirse a b7-h3 y cd3, y usos de los mismos

Country Status (21)

Country Link
US (1) US20190002563A1 (enExample)
EP (1) EP3337507A4 (enExample)
JP (1) JP2018523686A (enExample)
KR (1) KR20180038045A (enExample)
CN (1) CN107921130A (enExample)
AU (1) AU2016307955A1 (enExample)
CA (1) CA2995709A1 (enExample)
CL (1) CL2018000422A1 (enExample)
CO (1) CO2018001485A2 (enExample)
CR (1) CR20180105A (enExample)
EA (1) EA201890443A1 (enExample)
EC (1) ECSP18011248A (enExample)
HK (1) HK1249423A1 (enExample)
IL (1) IL257562A (enExample)
MA (1) MA42665A (enExample)
MX (1) MX2018001954A (enExample)
PE (1) PE20181066A1 (enExample)
PH (1) PH12018500363A1 (enExample)
TW (1) TW201718652A (enExample)
WO (1) WO2017030926A1 (enExample)
ZA (1) ZA201800955B (enExample)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10647768B2 (en) * 2014-05-29 2020-05-12 Macrogenics, Inc. Multi-chain polypeptide-containing tri-specific binding molecules
EA201790719A1 (ru) 2014-09-26 2017-07-31 Макродженикс, Инк. Биспецифические моновалентные диатела, которые способны связывать cd19 и cd3, а также их применения
CN108367069B (zh) 2015-12-14 2022-08-23 宏观基因有限公司 对于pd-1和ctla-4具有免疫反应性的双特异性分子及其使用方法
BR112019017628A2 (pt) 2017-02-24 2020-07-07 Macrogenics, Inc. molécula de ligação a cd137 x ta, composições farmacêuticas, uso da molécula de ligação a cd137 x ta, molécula de ligação a cd137, uso da molécula de ligação a cd137, molécula de ligação a her2/neu, uso da molécula de ligação a her2/neu, e uso de uma composição
MY200973A (en) 2017-04-11 2024-01-26 Inhibrx Inc Multispecific Polypeptide Constructs Having Constrained Cd3 Binding And Methods Of Using The Same
CN111356700A (zh) * 2017-09-08 2020-06-30 马弗里克治疗公司 受约束的条件性活化的结合蛋白
CN109939231A (zh) * 2017-12-21 2019-06-28 张曼 关于cd3×b7h3双特异性抗体定向杀伤膀胱癌细胞t24的应用
CN109939126A (zh) * 2017-12-21 2019-06-28 张曼 Cd3×b7h3双特异抗体定向杀伤耐阿霉素膀胱癌细胞pumc-91/adm的应用
CN109939232A (zh) * 2017-12-21 2019-06-28 张曼 关于cd3×b7h3双特异性抗体定向杀伤膀胱癌细胞pumc-91的应用
CN109939230A (zh) * 2017-12-21 2019-06-28 张曼 关于cd3×b7h3双特异性抗体定向杀伤耐顺铂膀胱癌细胞t24/ddp的应用
CN109971711A (zh) * 2017-12-27 2019-07-05 张曼 关于cd3×b7h3双特异性抗体定向杀伤人膀胱癌细胞的应用
CN111787949A (zh) * 2018-02-15 2020-10-16 宏观基因有限公司 变体cd3-结合结构域及其在用于治疗疾病的组合疗法中的用途
TW202010757A (zh) 2018-04-11 2020-03-16 美商英伊布里克斯公司 具有經受限cd3結合的多重特異性多肽構築體以及相關方法及用途
TWI848953B (zh) * 2018-06-09 2024-07-21 德商百靈佳殷格翰國際股份有限公司 針對癌症治療之多特異性結合蛋白
WO2020023553A1 (en) 2018-07-24 2020-01-30 Inhibrx, Inc. Multispecific polypeptide constructs containing a constrained cd3 binding domain and a receptor binding region and methods of using the same
CN109762068A (zh) * 2018-08-09 2019-05-17 源道隆（苏州）医学科技有限公司 一种可靶向ctla4和pd-1的单基因双特异性抗体及其应用
CN113166261A (zh) 2018-10-11 2021-07-23 印希比股份有限公司 B7h3单域抗体及其治疗性组合物
AU2019356573B2 (en) 2018-10-11 2025-12-18 Inhibrx Biosciences, Inc. PD-1 single domain antibodies and therapeutic compositions thereof
TWI821474B (zh) 2018-12-07 2023-11-11 大陸商江蘇恆瑞醫藥股份有限公司 Ｃｄ３抗體及其藥物用途
CN112969476B (zh) * 2018-12-07 2024-06-14 江苏恒瑞医药股份有限公司 多特异性蛋白分子
KR102732027B1 (ko) * 2019-07-09 2024-11-20 주식회사 와이바이오로직스 B7-h3(cd276)에 특이적으로 결합하는 항체 및 그의 용도
CN111454357B (zh) * 2019-08-14 2022-03-15 康诺亚生物医药科技（成都）有限公司 一种含有抗体的肿瘤治疗剂的开发和应用
EP3822288A1 (en) * 2019-11-18 2021-05-19 Deutsches Krebsforschungszentrum, Stiftung des öffentlichen Rechts Antibodies targeting, and other modulators of, the cd276 antigen, and uses thereof
KR20220119694A (ko) * 2019-12-23 2022-08-30 마크로제닉스, 인크. 암 치료를 위한 요법
EP4097129A1 (en) 2020-01-29 2022-12-07 Inhibrx, Inc. Cd28 single domain antibodies and multivalent and multispecific constructs thereof
MX2023000662A (es) * 2020-07-17 2023-02-27 Pfizer Anticuerpos terapeuticos y sus usos.
EP4032910A1 (en) * 2021-01-22 2022-07-27 ETH Zurich Bispecific binding agent that binds to cd3 and a fluorophore
WO2022232392A2 (en) * 2021-04-28 2022-11-03 Lyvgen Biopharma Holdings Limited Bi-specific antibodies comprising anti-b7h3 binding molecules
CN113527493B (zh) * 2021-07-20 2023-10-27 广州爱思迈生物医药科技有限公司 一种b7-h3抗体及其应用
US20230151095A1 (en) 2021-11-12 2023-05-18 Xencor, Inc. Bispecific antibodies that bind to b7h3 and nkg2d
CN114539420B (zh) * 2022-01-20 2024-05-17 荣昌生物制药(烟台)股份有限公司 抗b7-h3单克隆抗体、抗b7-h3×cd3双特异性抗体、制备方法及其应用
CN117660367A (zh) * 2022-09-06 2024-03-08 四川大学 一种ⅰ型单纯疱疹病毒毒株yd06、重组毒株及其用途
CN117903311B (zh) * 2024-03-20 2024-10-25 湖南卓润生物科技有限公司 sST2特异性结合蛋白及其制备方法和应用
WO2025245264A1 (en) * 2024-05-21 2025-11-27 Briapro Therapeutics Corp. Anti-b7-h3 antibodies and methods of use thereof
WO2026008059A1 (en) * 2024-07-04 2026-01-08 Nanjing Legend Biotech Co., Ltd. Anti-dll3 constructs and uses thereof

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2542256T3 (da) * 2010-03-04 2019-08-26 Macrogenics Inc Antistoffer reagerende med b7-h3, immunologisk aktive fragmenter deraf og anvendelser deraf
WO2012162067A2 (en) * 2011-05-21 2012-11-29 Macrogenics, Inc. Cd3-binding molecules capable of binding to human and non-human cd3
US10851178B2 (en) * 2011-10-10 2020-12-01 Xencor, Inc. Heterodimeric human IgG1 polypeptides with isoelectric point modifications
US9487587B2 (en) * 2013-03-05 2016-11-08 Macrogenics, Inc. Bispecific molecules that are immunoreactive with immune effector cells of a companion animal that express an activating receptor and cells that express B7-H3 and uses thereof
US20140302037A1 (en) * 2013-03-15 2014-10-09 Amgen Inc. BISPECIFIC-Fc MOLECULES
UA116479C2 (uk) * 2013-08-09 2018-03-26 Макродженікс, Інк. БІСПЕЦИФІЧНЕ МОНОВАЛЕНТНЕ Fc-ДІАТІЛО, ЯКЕ ОДНОЧАСНО ЗВ'ЯЗУЄ CD32B I CD79b, ТА ЙОГО ЗАСТОСУВАННЯ
EP2839842A1 (en) * 2013-08-23 2015-02-25 MacroGenics, Inc. Bi-specific monovalent diabodies that are capable of binding CD123 and CD3 and uses thereof
UA128469C2 (uk) * 2015-10-08 2024-07-24 Макродженікс, Інк. Спосіб лікування в7-н3-експресуючого раку

Also Published As

Publication number Publication date
AU2016307955A1 (en) 2018-03-08
CN107921130A (zh) 2018-04-17
EP3337507A1 (en) 2018-06-27
TW201718652A (zh) 2017-06-01
EA201890443A1 (ru) 2018-09-28
WO2017030926A1 (en) 2017-02-23
CR20180105A (es) 2018-06-12
IL257562A (en) 2018-04-30
HK1249423A1 (zh) 2018-11-02
ECSP18011248A (es) 2018-04-30
CA2995709A1 (en) 2017-02-23
CO2018001485A2 (es) 2018-07-10
PE20181066A1 (es) 2018-07-04
JP2018523686A (ja) 2018-08-23
MX2018001954A (es) 2018-11-09
ZA201800955B (en) 2018-11-28
EP3337507A4 (en) 2019-04-24
PH12018500363A1 (en) 2018-09-10
US20190002563A1 (en) 2019-01-03
MA42665A (fr) 2018-06-27
KR20180038045A (ko) 2018-04-13

Similar Documents

Publication Publication Date Title
ECSP18011248A (es) Diacuerpos monovalentes biespecíficos que son capaces de unirse a b7-h3 y cd3, y usos de los mismos
CO2018003452A2 (es) Anticuerpos biespecíficos contra el cd20 humano y el receptor de transferrina humano y métodos de uso
CO2018001149A2 (es) Anticuerpos monoclonales contra bcma
MX391279B (es) Anticuerpos biespecíficos contra cd3 y cd20.
CL2018001545A1 (es) Moléculas biespecíficas que tienen inmunorreactividad con pd-1 y ctla-4, y métodos de uso de las mismas
CL2018001512A1 (es) Anticuerpos anti-cd73 humanizados.
CR20150502A (es) Anticuerpos biespecíficos específicos para fap y dr5, anticuerpos específicos para dr5 y métodos de utilización
DOP2017000083A (es) Diacuerpos monovalentes biespecíficos que son capaces de unir cd19 y cd3, y usos de los mismos
MX2016012094A (es) Composiciones de anticuerpos para tratamiento tumoral.
CL2017001459A1 (es) Biarilo compuestos útiles para el tratamiento de enfermedades humanas en oncología, neurología e inmunología
MX381046B (es) Anticuerpos anti-csf1r e inhibidores de pd-1/pd-l1, y usos de los mismos para el tratamiento de cáncer remisión a las solicitudes relacionadas.
CO2017000016A2 (es) Diacuerpos heterodiméricos biespecíficos capaces de unirse en forma específica a un epítopo de p-cadherina y a un epítopo de cd3 que comprende una primera cadena polipeptídica y una segunda cadena polipeptídica y composiciones farmacéuticas de los mismos
GT201700131A (es) Composiciones y métodos para anticuerpos dirigidos a bmp6
MX2018007288A (es) Anticuerpos neutralizantes para el virus de inmunodeficiencia humana.
MX2020004503A (es) Anticuerpos cd3 humanizados o quimericos.
PE20160509A1 (es) Diacuerpos monovalentes biespecificos que son capaces de unir cd123 y cd3, y usos de los mismos
MX391171B (es) Anticuerpos anti-cd19 humano con alta afinidad
MX2017002230A (es) Anticuerpos anti-lag3 y fragmentos de union a antigeno.
MX380601B (es) Proteínas de unión a cd33 y cd3 biespecíficas.
MX2016001741A (es) Diacuerpos fc monovalentes biespecificos que son capaces de unirse a cd32b y cd79b y usos de los mismos.
MX2018005061A (es) Compuestos de interacción con glicanos y métodos de uso.
MX2018003183A (es) Proteinas de enlace de antigeno biespecifico y tetraespecifico tetravalentes y usos de las mismas.
PE20180315A1 (es) Anticuerpos para cd40
CL2019002735A1 (es) Anticuerpos que se unen a steap-1.
CL2016001753A1 (es) Anticuerpo monoclonal humanizado que se une específicamente a netrina-1, composiciones farmacéuticas y usos del anticuerpo para el tratamiento del cáncer